U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354074) titled 'Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP' on Jan. 15.
Brief Summary: The aim of this study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
Study Start Date: June 04, 2026
Study Type: INTERVENTIONAL
Condition:
Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, Philadelphia Chromosome...